Apex Medical Corp. (4106.TW)
TWD 24.5
(1.24%)
TWD 24.5
(1.24%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.13 Billion TWD | 6.71% |
| 2022 | 1.06 Billion TWD | 8.09% |
| 2021 | 986.95 Million TWD | 16.44% |
| 2020 | 847.63 Million TWD | -0.72% |
| 2019 | 853.81 Million TWD | -2.63% |
| 2018 | 876.87 Million TWD | -3.27% |
| 2017 | 906.52 Million TWD | 3.23% |
| 2016 | 878.18 Million TWD | -2.55% |
| 2015 | 901.16 Million TWD | -13.89% |
| 2014 | 1.04 Billion TWD | 22.98% |
| 2013 | 850.99 Million TWD | 14.76% |
| 2012 | 741.52 Million TWD | 17.03% |
| 2011 | 633.63 Million TWD | -0.32% |
| 2010 | 635.68 Million TWD | 6.32% |
| 2009 | 597.92 Million TWD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 280.46 Million TWD | -8.69% |
| 2024 Q2 | 263.63 Million TWD | -6.0% |
| 2023 Q3 | 245.12 Million TWD | -15.08% |
| 2023 Q4 | 307.15 Million TWD | 25.3% |
| 2023 FY | 1.13 Billion TWD | 6.71% |
| 2023 Q1 | 297.36 Million TWD | 11.92% |
| 2023 Q2 | 288.66 Million TWD | -2.92% |
| 2022 Q2 | 266.9 Million TWD | 7.58% |
| 2022 Q4 | 265.68 Million TWD | -7.14% |
| 2022 FY | 1.06 Billion TWD | 8.09% |
| 2022 Q3 | 286.1 Million TWD | 7.2% |
| 2022 Q1 | 248.09 Million TWD | 2.02% |
| 2021 Q3 | 248.59 Million TWD | -0.48% |
| 2021 Q4 | 243.18 Million TWD | -2.17% |
| 2021 Q1 | 245.39 Million TWD | 12.67% |
| 2021 Q2 | 249.78 Million TWD | 1.79% |
| 2021 FY | 986.95 Million TWD | 16.44% |
| 2020 Q2 | 223.81 Million TWD | 31.77% |
| 2020 Q1 | 169.84 Million TWD | -21.12% |
| 2020 FY | 847.63 Million TWD | -0.72% |
| 2020 Q4 | 217.79 Million TWD | -7.78% |
| 2020 Q3 | 236.17 Million TWD | 5.52% |
| 2019 Q3 | 201.51 Million TWD | -5.64% |
| 2019 FY | 853.81 Million TWD | -2.63% |
| 2019 Q1 | 223.4 Million TWD | -9.45% |
| 2019 Q2 | 213.56 Million TWD | -4.41% |
| 2019 Q4 | 215.33 Million TWD | 6.86% |
| 2018 Q1 | 205.17 Million TWD | -3.38% |
| 2018 FY | 876.87 Million TWD | -3.27% |
| 2018 Q4 | 246.7 Million TWD | 19.83% |
| 2018 Q3 | 205.89 Million TWD | -6.03% |
| 2018 Q2 | 219.09 Million TWD | 6.79% |
| 2017 Q4 | 212.35 Million TWD | -9.94% |
| 2017 Q1 | 211.42 Million TWD | -2.81% |
| 2017 Q3 | 235.78 Million TWD | -4.52% |
| 2017 Q2 | 246.95 Million TWD | 16.81% |
| 2017 FY | 906.52 Million TWD | 3.23% |
| 2016 FY | 878.18 Million TWD | -2.55% |
| 2016 Q1 | 227.87 Million TWD | -5.01% |
| 2016 Q2 | 240.58 Million TWD | 5.58% |
| 2016 Q3 | 192.18 Million TWD | -20.12% |
| 2016 Q4 | 217.53 Million TWD | 13.19% |
| 2015 Q4 | 239.9 Million TWD | 29.33% |
| 2015 Q3 | 185.49 Million TWD | -22.85% |
| 2015 Q2 | 240.42 Million TWD | 2.16% |
| 2015 Q1 | 235.34 Million TWD | -5.06% |
| 2015 FY | 901.16 Million TWD | -13.89% |
| 2014 Q4 | 247.87 Million TWD | -7.61% |
| 2014 Q3 | 268.28 Million TWD | 0.83% |
| 2014 Q1 | 264.31 Million TWD | 14.16% |
| 2014 FY | 1.04 Billion TWD | 22.98% |
| 2014 Q2 | 266.06 Million TWD | 0.66% |
| 2013 Q4 | 231.52 Million TWD | 16.46% |
| 2013 FY | 850.99 Million TWD | 14.76% |
| 2013 Q3 | 198.8 Million TWD | -13.01% |
| 2013 Q2 | 228.53 Million TWD | 18.95% |
| 2013 Q1 | 192.12 Million TWD | -1.06% |
| 2012 Q1 | 168.89 Million TWD | -0.02% |
| 2012 FY | 741.52 Million TWD | 17.03% |
| 2012 Q3 | 186.73 Million TWD | 3.99% |
| 2012 Q2 | 179.56 Million TWD | 6.31% |
| 2012 Q4 | 194.18 Million TWD | 3.99% |
| 2011 Q1 | 169.12 Million TWD | 26.32% |
| 2011 FY | 633.63 Million TWD | -0.32% |
| 2011 Q2 | 138.79 Million TWD | -17.93% |
| 2011 Q3 | 156.78 Million TWD | 12.96% |
| 2011 Q4 | 168.92 Million TWD | 7.75% |
| 2010 Q3 | 144.37 Million TWD | -28.42% |
| 2010 FY | 635.68 Million TWD | 6.32% |
| 2010 Q4 | 133.89 Million TWD | -7.26% |
| 2010 Q1 | 155.71 Million TWD | 0.0% |
| 2010 Q2 | 201.7 Million TWD | 29.53% |
| 2009 FY | 597.92 Million TWD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Excelsior Medical Co., Ltd. | 1.62 Billion TWD | 29.824% |
| OK Biotech Co., Ltd. | 196.88 Million TWD | -478.166% |
| Applied BioCode Corporation | 268.73 Million TWD | -323.577% |